Research Funding

ACTIVE Research Support

1 R33 CA202898-01, NIH/NCI                                   Queimado (PI)               03/01/2016/-04/30/2019
A novel molecular assay for early detection and assessment of cancer risk
The major goals of this project are: (1) to advance the development and standardization of q-PADDA for high-throughput DNA damage quantification in human samples; (2) to validate q-PADDA for DNA damage quantification and cancer risk assessment in populations with relevant mutagen exposure; and (3) to validate q-PADDA as a screening tool for the early detection of head and neck cancer.

1 R01 CA196200-01A1, NIH/NCI Benbrook (PI);         Queimado (Co-I) 07/01/2015/-06/30/2020
Ovarian Cancer Chemoprevention  
The goals of this project are to conduct a Phase 0 Clinical Trial of SHetA2 to determine the minimal dose needed to achieve micromolar blood and Fallopian tube tissue drug levels, to test the chemoprevention activity of SHetA2 in a mouse model of Fallopian tube tumorigenesis, and to study the mortalin interactome in the development of SHetA2 sensitivity during Fallopian tube tumorigenesis and as pharmacodynamic candidates for future chemoprevention clinical trials.

Oklahoma Tobacco Research Center (OTRC)              Queimado (PI)
Studying cancer risk and therapy resistance associated with electronic cigarette use

The goals of this project are to assess the potential role of electronic cigarette aerosol in cancer initiation and therapy resistance.

Oklahoma Tobacco Settlement Endowment (TSET),
McCaffree (PI)                        07/01/2014-06/30/2016
OTRC, 092-016-0002                                    Queimado (TSET Research Scholar)
The purpose of this agreement is to develop a nationally prominent tobacco research center in Oklahoma, consisting of research programs, statewide institutional collaborations, cessation services and supporting infrastructure that enhances the likelihood of successfully competing for significant extramural funds.

Presbyterian Health Foundation Chair in Otorhinolaryngology  
1/11/2002 - present                                                  Queimado (Chair)   
EC2221800: The purpose of this endowment is to foster head and neck cancer research by developing research resources within our department and providing research training for residents and fellows.

COMPLETED Research Support (past 3 years)

OTRC, C1081207                                          Queimado (PI),                              10/01/2013-06/30/2015
Quantification and mapping of DNA damage induced by e-cigarettes
This project focused on the cellular effects of first and second generation electronic cigarette aerosols.

OCAST, HR11-102                                        Queimado (PI)                              12/01/2011-11/31/2014
Predicting Oral Cancer Risk and Treatment Efficacy
Main goal: To use tissue bank samples to determine whether the levels of persistent DNA damage in head and neck cancer patients differed from a control cohort population and defined specific thresholds of risk.

OTRC, C1063706                                         Queimado (PI)                                 07/01/2012-6/30/2014
A Novel Assay to Predict Susceptibility to Tobacco-Induced Disease In Diverse Populations
The major goals of this project were to determine if the levels of tobacco-induced DNA damage in the oral mucosa of American Indians vary significantly within and between ethnic groups.

NIH/NIDCR, El-Naggar (PI)                              Queimado (Consultant)                 1/01/2010-12/31/2014
National Salivary Gland Tumor and Cell Line Biorepository, UT MD Anderson Cancer Center, Houston, TX
Duties: (a) To provide expertise in relation to establishment of the salivary gland tumor and cell line biorepository; (b) To provide expertise on cell line immortalization, stability and biological characterization.

College of Medicine Alumni Association,Ramachandran (PI)                                    07/01/2013-07/31/2014
Targeting the Cancer Stem Cells in Oral Cancer      Queimado (Co-I & Mentor)
The major goal of this project was to target WIF1 in oral cancer stem cells.


U.S. Patent Application 13/565,604: A Novel DNA Damage Detection Assay